Specialists On Call introduces post-acute care telemedicine platform

Specialists On Call (SOC), a supplier of telemedicine services and technology, has announced a new post-acute care solution to encompass telemedicine needs in the care continuum for acute and non-acute providers.

“We developed this scheduled consult offering to enable our clients to extend their telemedicine reach outside the four walls of their hospitals,” said Hammad Shah, CEO of SOC. “Now, we offer a singular platform for both acute and post-acute needs, which is consistent with our philosophy of introducing solutions that are easy and quick to deploy, require minimal up-front capital investment, and allow for rapid expansion.”

The SOC Scheduled Consult Manager and On-Demand Consult Manager systems use business rule engines for configuration into a healthcare organizations clinical, operational and business needs. While especially useful to accountable care organizations, integrated delivery networks and population management programs, the SOC tool can help with chronic care, prevent emergency department readmission, improve patient access and increase patient engagement.

“This is an answer to what our health systems and network partners have been asking SOC for some time: to consolidate their telemedicine platform with a single partner that offers an end-to-end integrated enterprise solution. The solution includes hardware and software, 24/7 operations support, clinical workflow optimization support, clinical resource management, analytics, and predictive modeling,” said Sean Banerjee, CTO of SOC. “SOC remains hardware agnostic, so the new platform will work with any laptop, phone, tablet, or telemedicine cart. This brings the cost of implementation down and leverages a health system or network’s existing infrastructure investments.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.